Public consultation on applications to be considered by the MSAC (July 2022)

Overview

Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 28-29 July 2022.

MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

Consultation input must be received by no later than Friday, 10 June 2022 for it to be considered by MSAC.

To provide input on any of the applications listed, please click on the relevant application link below. This will take you to the specific MSAC application webpage which includes further information about the medical service/ technology. 

You can then download and complete a consultation survey or provide a separate file with your input to commentsMSAC@health.gov.au

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:

Resubmissions:

1408.1 - A prognostic RT-qPCR test run locally for ER+ve /HER2-ve breast cancer that determines the risk of early and late metastasis in node negative and positive cancer under endocrine treatment

New applications:

1637 – Expanded Reproductive Carrier Screening of couples for joint carrier status of genes associated with autosomal recessive and X-linked conditions

1658 – Testing of tumour tissue to determine a positive homologous recombination deficiency status in women newly diagnosed with advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian tube or primary peritoneal cancer for access to PBS olaparib

1665 – Radiofrequency echographic multi spectrometry for bone density measurement and determination of osteopenia/osteoporosis

1668 – Whole body magnetic resonance imaging for detection of cancer in individuals with germline pathogenic TP53 variants

1671 - Targeted carrier testing for severe monogenic conditions

1672 – Procedures for the insertion or removal of a leadless permanent pacemaker for the treatment of bradyarrhythmia

1686 –¹⁷⁷Lutetium PSMA i&t for metastatic castrate resistant prostate cancer

1689 – Quantification of NT-proBNP in patients with systemic sclerosis, and in patients with diagnosed pulmonary arterial hypertension

1690 – Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell to treat refractory or relapsed multiple myeloma

1697 - Review of different minimally invasive therapeutic approaches for the management of patients with benign prostatic hyperplasia

1698 – Chronic Pain MedsCheck Trial

Item withdrawn:

Please note that Application 1627 - Point-of-care test for diagnosis of Neisseria gonorrhoea, Chlamydia trachomatis and Trichomonas vaginalis infection in Aboriginal and Torres Strait Islander patients presenting at health services in areas with high sexually transmitted infection burden has been withdrawn from the June 2022 ESC Meeting and will not be considered by MSAC at its 28-29 July 2022 meeting.

Please view the MSAC meeting agenda webpage for information on items scheduled for each meeting.

What happens next

Once the consultation closes, submissions will be compiled and considered by MSAC.

Once it has finalised its appraisal of an application for public funding, MSAC publishes a Public Summary Document (PSD). The PSD captures MSAC deliberations and key advice to the Minister, which is generally to either support funding; not support funding; or defer consideration. 

PSDs are generally published approximately three (3) months after the MSAC meeting at which the application was considered. The PSD can be located on the relevant application webpage on the MSAC website.